Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of “Buy” by Brokerages

Shares of Immunic, Inc. (NASDAQ:IMUX) have been assigned a consensus rating of “Buy” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $48.40.

A number of equities analysts have weighed in on the company. Zacks Investment Research raised Immunic from a “sell” rating to a “hold” rating in a research report on Thursday, September 9th. HC Wainwright reduced their price target on Immunic from $40.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, September 7th. Finally, Wedbush cut their price objective on Immunic from $68.00 to $61.00 and set an “outperform” rating for the company in a report on Monday, August 9th.

NASDAQ IMUX traded up $0.35 during trading hours on Wednesday, reaching $9.57. 831 shares of the company’s stock were exchanged, compared to its average volume of 202,121. The company’s 50-day moving average is $9.43 and its two-hundred day moving average is $12.30. Immunic has a one year low of $7.69 and a one year high of $28.21. The company has a market capitalization of $251.20 million, a price-to-earnings ratio of -2.55 and a beta of 2.03.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Friday, August 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.14). Analysts predict that Immunic will post -3.91 EPS for the current year.

A number of institutional investors have recently made changes to their positions in IMUX. BlackRock Inc. lifted its holdings in Immunic by 53.3% during the 2nd quarter. BlackRock Inc. now owns 1,126,293 shares of the company’s stock valued at $13,808,000 after purchasing an additional 391,501 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in Immunic by 111.8% during the 1st quarter. Point72 Asset Management L.P. now owns 433,047 shares of the company’s stock valued at $6,903,000 after purchasing an additional 228,547 shares during the last quarter. State Street Corp lifted its holdings in Immunic by 41.1% during the 2nd quarter. State Street Corp now owns 351,296 shares of the company’s stock valued at $4,307,000 after purchasing an additional 102,277 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Immunic by 57.3% during the 2nd quarter. Geode Capital Management LLC now owns 258,569 shares of the company’s stock valued at $3,170,000 after purchasing an additional 94,139 shares during the last quarter. Finally, Millennium Management LLC increased its position in Immunic by 50.4% during the 2nd quarter. Millennium Management LLC now owns 239,556 shares of the company’s stock worth $2,937,000 after buying an additional 80,233 shares during the period. 35.96% of the stock is owned by institutional investors and hedge funds.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856.

Recommended Story: S&P/ASX 200 Index

Analyst Recommendations for Immunic (NASDAQ:IMUX)

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.